Literature DB >> 15964062

Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer.

Joseph D Martin1, Blake Gilks, Peter Lim.   

Abstract

OBJECTIVE: To explore factors that determine the response of endometrial cancer to radiation therapy. Such factors may influence treatment outcome and yield predictive information about individual patients and their tumors.
METHODS: A retrospective study of the complete pathologic response (pCR) rates in the hysterectomy specimens of patients, who had undergone pre-operative radiotherapy for > or = Stage II biopsy-proven endometrial carcinoma, was performed. 62 patient records were reviewed with respect to patient characteristics, tumor stage, histological grade and subtype, radiation technique and dose, and presence or absence of pCR in the post-operative hysterectomy specimen.
RESULTS: 24 of 62 specimens exhibited a pCR. The only significant factor with respect to pCR was presence of uterine papillary serous carcinoma (UPSC). None of the seven cases of UPSC displayed a pCR (P = 0.036 Fischer's exact test), despite not differing from the non-UPSC cases in any other tumor, treatment, or patient factors. No factors were found that separated non-UPSC cases with a pCR from those without.
CONCLUSIONS: These data suggest an intrinsic radioresistance within UPSC, which may have implications for future treatment strategies. UPSC has documented genetic aberrations that may account for this, although its true radiosensitivity has yet to be quantitated directly. Future studies should focus on the molecular basis of its response to radiation. The reasons for the heterogeneous response of non-UPSC has yet to be elucidated and should also be investigated.

Entities:  

Mesh:

Year:  2005        PMID: 15964062     DOI: 10.1016/j.ygyno.2005.04.009

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

2.  Postoperative Adjuvant Chemoradiotherapy Versus Chemotherapy Alone for Stage III Endometrial Cancer: A Multicenter Retrospective Study.

Authors:  Ji Geun Yoo; Jin Hwi Kim; Chan Joo Kim; Hae Nam Lee; Min Jong Song; Dong Choon Park; Joo Hee Yoon; Sang Il Kim; Soo Young Hur; Sung Jong Lee
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

3.  A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.

Authors:  Howard D Homesley; Virginia Filiaci; Susan K Gibbons; Harry J Long; David Cella; Nick M Spirtos; Robert T Morris; Koen DeGeest; Roger Lee; Anthony Montag
Journal:  Gynecol Oncol       Date:  2008-12-23       Impact factor: 5.482

4.  erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy.

Authors:  Karim S Elsahwi; Alessandro D Santin
Journal:  Obstet Gynecol Int       Date:  2011-08-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.